

2019 Future of Critical Limb Ischemia R&D Pipeline Drugs and Companies- Analysis of Global Critical Limb Ischemia Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/28A6E6C6889EN.html>

Date: January 2019

Pages: 100

Price: US\$ 2,199.00 (Single User License)

ID: 28A6E6C6889EN

Abstracts

The global demand for Critical Limb Ischemia treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Critical Limb Ischemia pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Critical Limb Ischemia pipeline companies from advancing their products into Phase 3 or Phase 4.

Critical Limb Ischemia Report Description

The H1 2019 pipeline review report on Critical Limb Ischemia pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Critical Limb Ischemia pipeline compounds.

The Critical Limb Ischemia pipeline guide presents information on all active drugs currently being developed for Critical Limb Ischemia. The research work provides details of active therapeutic candidates in different phases including discovery,

research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Critical Limb Ischemia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Critical Limb Ischemia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Critical Limb Ischemia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Critical Limb Ischemia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Critical Limb Ischemia pipeline report includes

An overview of Critical Limb Ischemia disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Critical Limb Ischemia pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Critical Limb Ischemia pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Critical Limb Ischemia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and

company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL CRITICAL LIMB ISCHEMIA PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Critical Limb Ischemia Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Critical Limb Ischemia pipeline, H1- 2019
- 3.5 Mechanism of Action wise Critical Limb Ischemia Pipeline Candidates

4. ANAEROPHARMA SCIENCE, INC. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 4.1 Anaeropharma Science, Inc. Business Profile
- 4.2 Anaeropharma Science, Inc. Critical Limb Ischemia Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ANGES MG, INC. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 5.1 AnGes MG, Inc. Business Profile
- 5.2 AnGes MG, Inc. Critical Limb Ischemia Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. ANTIDOTE THERAPEUTICS INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 6.1 Antidote Therapeutics Inc Business Profile
- 6.2 Antidote Therapeutics Inc Critical Limb Ischemia Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. APCETH BIOPHARMA GMBH CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 7.1 Apceth Biopharma GmbH Business Profile
- 7.2 Apceth Biopharma GmbH Critical Limb Ischemia Drug Details

- 7.2.1 Drug Snapshot
 - 7.2.1.1 Originator
 - 7.2.1.2 Collaborator/Co-Developer
 - 7.2.1.3 Route of Administration
 - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 7.2.1.5 Area
 - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. ATHERSYS, INC. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 8.1 Athersys, Inc. Business Profile
- 8.2 Athersys, Inc. Critical Limb Ischemia Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. BIOGENCELL LTD. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 9.1 BioGenCell Ltd. Business Profile
- 9.2 BioGenCell Ltd. Critical Limb Ischemia Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation

- 9.2.1.5 Area
- 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. BIOTECH HOLDINGS CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 10.1 Biotech Holdings Business Profile
- 10.2 Biotech Holdings Critical Limb Ischemia Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11. CALADRIUS BIOSCIENCES, INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 11.1 Caladrius Biosciences, Inc Business Profile
- 11.2 Caladrius Biosciences, Inc Critical Limb Ischemia Drug Details
 - 11.2.1 Drug Snapshot
 - 11.2.1.1 Originator
 - 11.2.1.2 Collaborator/Co-Developer
 - 11.2.1.3 Route of Administration
 - 11.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 11.2.1.5 Area
 - 11.2.1.6 Type of Molecular Entity
- 11.3 Current Status
- 11.4 Drug Overview

- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12. CONSTANT PHARMACEUTICALS LLC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 12.1 Constant Pharmaceuticals LLC Business Profile
- 12.2 Constant Pharmaceuticals LLC Critical Limb Ischemia Drug Details
 - 12.2.1 Drug Snapshot
 - 12.2.1.1 Originator
 - 12.2.1.2 Collaborator/Co-Developer
 - 12.2.1.3 Route of Administration
 - 12.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 12.2.1.5 Area
 - 12.2.1.6 Type of Molecular Entity
- 12.3 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. CYNATA THERAPEUTICS LIMITED CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 13.1 Cynata Therapeutics Limited Business Profile
- 13.2 Cynata Therapeutics Limited Critical Limb Ischemia Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14. HEMOSTEMIX INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 14.1 Hemostemix Inc Business Profile
- 14.2 Hemostemix Inc Critical Limb Ischemia Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. HISTOCELL, S.L CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 15.1 Histocell, S.L Business Profile
- 15.2 Histocell, S.L Critical Limb Ischemia Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. ID PHARMA CO., LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 16.1 ID Pharma Co., Ltd Business Profile
- 16.2 ID Pharma Co., Ltd Critical Limb Ischemia Drug Details

- 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer
 - 16.2.1.3 Route of Administration
 - 16.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 16.2.1.5 Area
 - 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. JUVENTAS THERAPEUTICS, INC. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 17.1 Juventas Therapeutics, Inc. Business Profile
- 17.2 Juventas Therapeutics, Inc. Critical Limb Ischemia Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. KASIAK RESEARCH PVT. LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 18.1 Kasiak Research Pvt. Ltd Business Profile
- 18.2 Kasiak Research Pvt. Ltd Critical Limb Ischemia Drug Details
 - 18.2.1 Drug Snapshot
 - 18.2.1.1 Originator
 - 18.2.1.2 Collaborator/Co-Developer
 - 18.2.1.3 Route of Administration

- 18.2.1.4 Orphan Drug/Fast Track/Special Designation
- 18.2.1.5 Area
- 18.2.1.6 Type of Molecular Entity
- 18.3 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19. LIFECELLS LLC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 19.1 LifeCells LLC Business Profile
- 19.2 LifeCells LLC Critical Limb Ischemia Drug Details
 - 19.2.1 Drug Snapshot
 - 19.2.1.1 Originator
 - 19.2.1.2 Collaborator/Co-Developer
 - 19.2.1.3 Route of Administration
 - 19.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 19.2.1.5 Area
 - 19.2.1.6 Type of Molecular Entity
- 19.3 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20. NEUROFX INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 20.1 Neurofx Inc Business Profile
- 20.2 Neurofx Inc Critical Limb Ischemia Drug Details
 - 20.2.1 Drug Snapshot
 - 20.2.1.1 Originator
 - 20.2.1.2 Collaborator/Co-Developer
 - 20.2.1.3 Route of Administration
 - 20.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 20.2.1.5 Area
 - 20.2.1.6 Type of Molecular Entity
- 20.3 Current Status
- 20.4 Drug Overview

- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21. PHARMICELL CO., LTD. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 21.1 Pharmicell Co., Ltd. Business Profile
- 21.2 Pharmicell Co., Ltd. Critical Limb Ischemia Drug Details
 - 21.2.1 Drug Snapshot
 - 21.2.1.1 Originator
 - 21.2.1.2 Collaborator/Co-Developer
 - 21.2.1.3 Route of Administration
 - 21.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 21.2.1.5 Area
 - 21.2.1.6 Type of Molecular Entity
- 21.3 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22. PLURISTEM THERAPEUTICS INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 22.1 Pluristem Therapeutics Inc Business Profile
- 22.2 Pluristem Therapeutics Inc Critical Limb Ischemia Drug Details
 - 22.2.1 Drug Snapshot
 - 22.2.1.1 Originator
 - 22.2.1.2 Collaborator/Co-Developer
 - 22.2.1.3 Route of Administration
 - 22.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 22.2.1.5 Area
 - 22.2.1.6 Type of Molecular Entity
- 22.3 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23. RENEURON GROUP PLC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 23.1 ReNeuron Group plc Business Profile
- 23.2 ReNeuron Group plc Critical Limb Ischemia Drug Details
 - 23.2.1 Drug Snapshot
 - 23.2.1.1 Originator
 - 23.2.1.2 Collaborator/Co-Developer
 - 23.2.1.3 Route of Administration
 - 23.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 23.2.1.5 Area
 - 23.2.1.6 Type of Molecular Entity
- 23.3 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24. REVEN PHARMACEUTICALS INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 24.1 Reven Pharmaceuticals Inc Business Profile
- 24.2 Reven Pharmaceuticals Inc Critical Limb Ischemia Drug Details
 - 24.2.1 Drug Snapshot
 - 24.2.1.1 Originator
 - 24.2.1.2 Collaborator/Co-Developer
 - 24.2.1.3 Route of Administration
 - 24.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 24.2.1.5 Area
 - 24.2.1.6 Type of Molecular Entity
- 24.3 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. REXGENERO LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 25.1 Rexgenero Ltd Business Profile
- 25.2 Rexgenero Ltd Critical Limb Ischemia Drug Details

- 25.2.1 Drug Snapshot
 - 25.2.1.1 Originator
 - 25.2.1.2 Collaborator/Co-Developer
 - 25.2.1.3 Route of Administration
 - 25.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 25.2.1.5 Area
 - 25.2.1.6 Type of Molecular Entity

25.3 Current Status

25.4 Drug Overview

25.5 Drug Mechanism of Action

25.6 Clinical/Pre-clinical Trial Details

25.7 Latest Drug Developments

26. SYMIC BIO, INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

26.1 Symic Bio, Inc Business Profile

26.2 Symic Bio, Inc Critical Limb Ischemia Drug Details

- 26.2.1 Drug Snapshot
 - 26.2.1.1 Originator
 - 26.2.1.2 Collaborator/Co-Developer
 - 26.2.1.3 Route of Administration
 - 26.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 26.2.1.5 Area
 - 26.2.1.6 Type of Molecular Entity

26.3 Current Status

26.4 Drug Overview

26.5 Drug Mechanism of Action

26.6 Clinical/Pre-clinical Trial Details

26.7 Latest Drug Developments

27. TAIGEN BIOTECHNOLOGY CO LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

27.1 TaiGen Biotechnology Co Ltd Business Profile

27.2 TaiGen Biotechnology Co Ltd Critical Limb Ischemia Drug Details

- 27.2.1 Drug Snapshot
 - 27.2.1.1 Originator
 - 27.2.1.2 Collaborator/Co-Developer
 - 27.2.1.3 Route of Administration

- 27.2.1.4 Orphan Drug/Fast Track/Special Designation
- 27.2.1.5 Area
- 27.2.1.6 Type of Molecular Entity
- 27.3 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28. TAIWAN BIO THERAPEUTICS CO LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 28.1 Taiwan Bio Therapeutics Co Ltd Business Profile
- 28.2 Taiwan Bio Therapeutics Co Ltd Critical Limb Ischemia Drug Details
 - 28.2.1 Drug Snapshot
 - 28.2.1.1 Originator
 - 28.2.1.2 Collaborator/Co-Developer
 - 28.2.1.3 Route of Administration
 - 28.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 28.2.1.5 Area
 - 28.2.1.6 Type of Molecular Entity
- 28.3 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29. TIKOMED AB CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 29.1 TikoMed AB Business Profile
- 29.2 TikoMed AB Critical Limb Ischemia Drug Details
 - 29.2.1 Drug Snapshot
 - 29.2.1.1 Originator
 - 29.2.1.2 Collaborator/Co-Developer
 - 29.2.1.3 Route of Administration
 - 29.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 29.2.1.5 Area
 - 29.2.1.6 Type of Molecular Entity
- 29.3 Current Status

- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30. U.S. STEM CELL INC CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 30.1 U.S. Stem Cell Inc Business Profile
- 30.2 U.S. Stem Cell Inc Critical Limb Ischemia Drug Details
 - 30.2.1 Drug Snapshot
 - 30.2.1.1 Originator
 - 30.2.1.2 Collaborator/Co-Developer
 - 30.2.1.3 Route of Administration
 - 30.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 30.2.1.5 Area
 - 30.2.1.6 Type of Molecular Entity
- 30.3 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31. VESSL THERAPEUTICS LTD. CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 31.1 VESSL Therapeutics Ltd. Business Profile
- 31.2 VESSL Therapeutics Ltd. Critical Limb Ischemia Drug Details
 - 31.2.1 Drug Snapshot
 - 31.2.1.1 Originator
 - 31.2.1.2 Collaborator/Co-Developer
 - 31.2.1.3 Route of Administration
 - 31.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 31.2.1.5 Area
 - 31.2.1.6 Type of Molecular Entity
- 31.3 Current Status
- 31.4 Drug Overview
- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32. VIROMED CO LTD CRITICAL LIMB ISCHEMIA PIPELINE DETAILS

- 32.1 ViroMed Co Ltd Business Profile
- 32.2 ViroMed Co Ltd Critical Limb Ischemia Drug Details
 - 32.2.1 Drug Snapshot
 - 32.2.1.1 Originator
 - 32.2.1.2 Collaborator/Co-Developer
 - 32.2.1.3 Route of Administration
 - 32.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 32.2.1.5 Area
 - 32.2.1.6 Type of Molecular Entity
- 32.3 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

20. LATEST CRITICAL LIMB ISCHEMIA DRUG PIPELINE DEVELOPMENTS, 2019

21. APPENDIX

- 21.1 About Us
- 21.2 Sources and Methodology
- 21.3 Contact Information

I would like to order

Product name: 2019 Future of Critical Limb Ischemia R&D Pipeline Drugs and Companies- Analysis of Global Critical Limb Ischemia Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/28A6E6C6889EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/28A6E6C6889EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970